About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in North Carolina | 20,428 Studies Near You | Clareo Health

Clinical Trials LocationsNorth Carolina

Clinical Trials in North Carolina

Discover 20,428 clinical trials near North Carolina. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 15681-15700 of 20,428 trials

COMPLETEDPhase 325 miles

Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies

NCT00688519

The purpose of the study is to demonstrate the safety and efficacy of U0267 in subjects with plaque-type psoriasis.

Stiefel, a GSK Company336 participantsStarted Mar 2008

San Diego, California, United States • Denver, Colorado, United States • Miami, Florida, United States +10 more locations

COMPLETEDPhase 231 miles

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.

NCT00603278

This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.

GlaxoSmithKline622 participantsStarted Dec 2007

Phoenix, Arizona, United States • Fort Smith, Arkansas, United States • Little Rock, Arkansas, United States +152 more locations

Find Trials by Condition in North Carolina

Breast Cancerin North Carolina Lung Cancerin North Carolina Prostate Cancerin North Carolina Colorectal Cancerin North Carolina Melanomain North Carolina Leukemiain North Carolina Lymphomain North Carolina Pancreatic Cancerin North Carolina Ovarian Cancerin North Carolina Brain Cancerin North Carolina

Data from ClinicalTrials.govTerms

COMPLETEDPhase 241 miles

PF-06372865 In Subjects With Chronic Low Back Pain

NCT02262754

PF-06372865 In Subjects With Chronic Low Back Pain

Chronic Low Back Pain

Pfizer302 participantsStarted Oct 2014

Mesa, Arizona, United States • Phoenix, Arizona, United States • Anaheim, California, United States +43 more locations

COMPLETEDPhase 341 miles

Radiation Therapy in Treating Patients With Stage II Cancer of the Vocal Cord

NCT00002727

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which radiation therapy regimen is more effective in treating patients with stage II cancer of the vocal cord. PURPOSE: Randomized phase III trial to compare two regimens of radiation therapy in treating patients who have stage II cancer of the vocal cord.

Head and Neck Cancer

Radiation Therapy Oncology Group250 participantsStarted Apr 1996

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Huntsville, Alabama, United States +234 more locations

COMPLETEDPhase 341 miles

Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)

NCT00358436

To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.

Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca804 participantsStarted Aug 2006

Jasper, Alabama, United States • Ozark, Alabama, United States • Phoenix, Arizona, United States +117 more locations

COMPLETEDPhase 346 miles

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

NCT00932893

This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after failure of one previous chemotherapy regimen that included one platinum drug.

Carcinoma, Non-Small-Cell Lung

Pfizer347 participantsStarted Sep 2009

Little Rock, Arkansas, United States • Bakersfield, California, United States • Beverly Hills, California, United States +261 more locations

COMPLETEDNA46 miles

Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.

NCT01320293

Severe psoriasis has been demonstrated to be associated with decreased endothelial function and an increase risk of future coronary events. Although systemic therapy with immunomodulatory agents has been shown to improve psoriatic symptoms, its effects on systemic inflammation and endothelial function are unknown. In this study we want to assess the cardiovascular risks factors, endothelial dysfunction and inflammatory markers before and after treatment of moderate to severe psoriasis with an FDA-approved biologic agent, adalimumab (Humira).

University of North Carolina, Chapel Hill18 participantsStarted Mar 2011

Chapel Hill, North Carolina, United States

COMPLETEDPhase 459 miles

Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

NCT01574703

Non-treatment extension to study A3051123, aimed at collecting data on cardiovascular safety for all participants in the A3051123 trial for an additional 28 weeks, allowing for a total of 52 weeks of cardiovascular safety data collection.

Smoking Cessation

Pfizer4,595 participantsStarted May 2012

Mobile, Alabama, United States • Encino, California, United States • Escondido, California, United States +131 more locations

COMPLETEDPhase 365 miles

A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00500318

This study evaluated the effect of inhaled aclidinium bromide on exercise endurance and in reducing resting and dynamic lung hyperinflation in patients with moderate to severe COPD. It was 9 weeks in duration, consisting of; a 2-week run-in period, 6 weeks of double-blind treatment, and a 1-week follow-up phone call. All patients meeting the eligibility criteria were randomized to one of two treatment groups: aclidinium bromide or placebo.

Pulmonary Disease, Chronic Obstructive

AstraZeneca181 participantsStarted Jul 2007

Jasper, Alabama, United States • Phoenix, Arizona, United States • Long Beach, California, United States +49 more locations

TERMINATEDPhase 2/366 miles

Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer

NCT01383148

This is a Phase IIb/III randomized, double-blind, placebo-controlled study to compare the efficacy and safety of first-line therapy combined with TG4010 or placebo in stage IV non-small cell lung cancer (NSCLC). TG4010 is a suspension of recombinant Modified Vaccinia virus strain Ankara (MVA strain) carrying coding sequences for human MUC1 antigen and human interleukin-2 (IL2). TG4010 has been developed for use as an immunotherapy in cancer patients whose tumors express the MUC1 antigen. TG4010 is intended to induce a MUC1-specific cellular immune response and to produce a non-specific activation of several components of the immune system.

Non-Small-Cell Lung Carcinoma

Transgene222 participantsStarted Apr 2012

Scottsdale, Arizona, United States • Topeka, Kansas, United States • Louisville, Kentucky, United States +69 more locations

COMPLETEDPhase 366 miles

Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures

NCT00104416

This study is being conducted to compare the efficacy and safety of LAMICTAL (lamotrigine) extended-release with placebo in the treatment of Primary Generalized Tonic-Clonic (PGTC) seizures. LAMICTAL extended-release is an investigational drug. Placebo tablets look like LAMICTAL extended-release tablets but do not contain active medication. In this study, LAMICTAL extended-release or placebo tablets will be added to current seizure treatments.

Epilepsy, Tonic-Clonic

GlaxoSmithKline153 participantsStarted Dec 2004

Anniston, Alabama, United States • Birmingham, Alabama, United States • Northport, Alabama, United States +143 more locations

COMPLETEDPhase 366 miles

Efficacy and Safety of GTR in Comparison to Copaxone®

NCT01489254

The purpose of this study is demonstrate that efficacy and safety of Synthon's glatiramer acetate (GTR) is equivalent to Copaxone® (Teva) in patients with relapsing remitting multiple sclerosis

Multiple Sclerosis

Synthon BV794 participantsStarted Oct 2011

Irvine, California, United States • Port Charlotte, Florida, United States • Sunrise, Florida, United States +130 more locations

COMPLETEDPhase 366 miles

Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure

NCT00624065

Randomized, double-blind, parallel group, multicenter study of subjects with Stage 1 or 2 essential hypertension who are not at target blood pressure (\<140/90mmHg) at Baseline. Subjects will be randomized to receive either carvedilol CR + lisinopril or lisinopril + placebo. Subjects will be uptitrated over a 6 week period until target blood pressure (\<140/90mmHg) is met. The primary objective of the study is to compare the proportion of subjects who achieve target blood pressure after 6 weeks of treatment.

GlaxoSmithKline348 participantsStarted Mar 2008

Mobile, Alabama, United States • Chandler, Arizona, United States • Glendale, Arizona, United States +73 more locations

COMPLETED137 miles

Multicenter International Cross-Sectional Evaluation of Pulmonary Alveolar Proteinosis Trial

NCT03007134

The purpose of this study is to (1) compare a technically improved assay with an existing assay used to measure serum anti-GM-CSF antibodies in stored serum samples previously obtained from patients diagnosed with either primary, secondary, congenital or idiopathic pulmonary alveolar proteinosis (PAP), other chronic diseases or disease-free, healthy individuals; (2) determine the prevalence and levels of anti-GM-CSF autoantibodies and (3) define the breadth of the autoimmune antibody responses in primary PAP patients from the United States, Japan, Australia, and Europe using previously collected serum samples; and (4) using a chart review approach, compare the clinical, radiologic and laboratory features of primary PAP patients to determine if differences exist among patients in these globally geographically distributed regions.

Pulmonary Alveolar Proteinosis

Children's Hospital Medical Center, Cincinnati73 participantsStarted Jul 2007

Greenville, North Carolina, United States • Cincinnati, Ohio, United States • Essen, Germany +3 more locations

COMPLETEDPhase 3291 miles

Evaluation of Skin Testing Reagents for Penicillin Allergy

NCT01818336

A self- or parent-reported history of penicillin allergy excludes approximately 10% of the US population from receiving penicillin (Kerr 1994, Kagy, Blaiss 1998, Solensky et al. 2000, Neugut et al. 2001). Yet approximately 80% of patients labeled as allergic to the penicillins can safely take these antibiotics without fear of a life-threatening reaction (Gadde et al. 1993, Macy et al. 1997). The outcomes of this erroneous classification of patients include unnecessary denial of an effective and well-tolerated class of antibiotics, which are often the treatment of choice. The primary aim of skin testing with the Penicillin Skin Test Kit is to identify subjects at very low risk of developing acute IgE-dependent reactions when given a penicillin or cross-reacting drug. The negative predictive value (NPV) of skin testing is assessed by oral challenge with a penicillin.

History of IgE Dependent Reaction to a Penicillin Product

AllerQuest LLC481 participantsStarted Dec 2012

Homewood, Alabama, United States • Tucson, Arizona, United States • Walnut Creek, California, United States +10 more locations

COMPLETEDPhase 4333 miles

Continuous Chest Compressions vs AHA Standard CPR of 30:2

NCT01372748

The primary aim of the trial is to compare survival to hospital discharge after continuous chest compressions (CCC) versus standard American Heart Association (AHA) recommended cardiopulmonary resuscitation (CPR) with interrupted chest compressions (ICC) in patients with out-of-hospital cardiac arrest (OOHCA). The primary null hypothesis will be that the rate of survival to hospital discharge is not affected by use of continuous compressions with passive or positive pressure ventilation (intervention group) versus CPR with compressions interrupted for ventilation at a ratio of 30:2 (control group).

Out of Hospital Cardiac Arrest

University of Washington23,711 participantsStarted Jun 2011

Birmingham, Alabama, United States • Pittsburgh, Pennsylvania, United States • Dallas, Texas, United States +4 more locations

TERMINATEDPhase 2/3392 miles

Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes

NCT00891995

The purpose of this study is to find out if very tight blood glucose control from the onset of Type 1 Diabetes can preserve beta cell function. Study subjects will be randomly assigned to receive either standard diabetes management or intensive diabetes management, which involves several days of closed loop therapy followed by home use of a continuous glucose monitor and insulin pump.

Type 1 Diabetes

Jaeb Center for Health Research71 participantsStarted Sep 2010

Stanford, California, United States • Aurora, Colorado, United States • New Haven, Connecticut, United States +2 more locations

COMPLETEDPhase 4418 miles

Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.

NCT00555061

A study to evaluate the pharmacokinetics of Retapamulin Ointment, 1%, in pediatric subjects (2-24 months) with secondarily-infected traumatic lesions, secondarily-infected dermatoses, or impetigo (bullous and non-bullous).

Skin Infections, Bacterial

GlaxoSmithKline60 participantsStarted Sep 2007

Tuscaloosa, Alabama, United States • Bentonville, Arkansas, United States • Orange, California, United States +22 more locations

TERMINATEDPhase 2471 miles

Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy

NCT01813019

The purpose of this study is to determine whether AFQ056 as an add on therapy to SSRIs can have beneficial effects by reducing the total score of Y-BOCS (Yale and Brown Obsessive Compulsive Scale) in OCD patients resistant to SSRI treatment (failed SSRI over 12 weeks at appropriate doses).

Patient Diagnosed With OCD and Resistant to SSRI TreatmentFailed SSRI Over 12 Weeks at Appropriate Doses

Novartis Pharmaceuticals50 participantsStarted Nov 2013

San Diego, California, United States • Watertown, Massachusetts, United States • Brooklyn, New York, United States +12 more locations

COMPLETEDPhase 1483 miles

A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

NCT00741403

An open label, dose-escalation study to evaluate safety, tolerability, maximum tolerated dose (MTD), efficacy, and pharmacokinetics (PKs) of CPI-613 given twice weekly for three consecutive weeks in cancer patients The objectives of this study are: * To determine the safety and MTD of CPI-613 when administered 2x weekly for 3 consecutive weeks. * To determine pharmacokinetics of CPI-613 following intravenous (IV) administration. * To observe the anti-tumor effects of CPI-613, if any occur.

Advanced CancerMetastatic CancerLymphoma+2 more

Cornerstone Pharmaceuticals39 participantsStarted Aug 2008

Peoria, Arizona, United States • The Bronx, New York, United States • Dallas, Texas, United States +1 more locations

PreviousPage 785 of 1022Next

Diabetes

in North Carolina

Heart Diseasein North Carolina